Streetbeat News

Price Targets

COMM

Northland Capital Markets has maintained a Market Perform rating on CommScope Holding Company (NASDAQ:COMM) and raised the price target from $1.25 to $2.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:46 am

NOTE

Northland Capital Markets analyst Michael Latimore maintains an Outperform rating on FiscalNote Holdings (NYSE:NOTE) but lowers the price target from $6 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:43 am

BRNS

HC Wainwright & Co. analyst Yi Chen reiterates a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS) and maintains a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:42 am

EVLV

Northland Capital Markets analyst Michael Latimore maintains an Outperform rating on Evolv Technologies (NASDAQ:EVLV) but lowers the price target from $6.5 to $5.5.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:41 am

PCRX

HC Wainwright & Co. has maintained a Buy rating on Pacira BioSciences (NASDAQ:PCRX) but lowered the price target from $57 to $39.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:39 am

SABS

Chardan Capital analyst Keay Nakae maintains a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) with a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:37 am

EE

Northland Capital Markets has maintained an Outperform rating on Excelerate Energy (NYSE:EE) and raised the price target from $23 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:37 am

RVMD

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Revolution Medicines (NASDAQ:RVMD) and maintained a $56 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:32 am

PGY

Canaccord Genuity analyst Joseph Vafi maintains a Buy rating on Pagaya Techs (NASDAQ:PGY) with a $42 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:31 am

TRML

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Tourmaline Bio (NASDAQ:TRML) and maintained a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:31 am